BioWorld

April 5, 2006

View Archived Issues

Stapling Synthetic Biologics To Attack Difficult Cancer Targets

Read More

Nabi Licenses Rights In U.S., Canada For Fresenius Drug

Read More

Clinic Roundup

Read More

Other News To Note

Read More

Financings Roundup

Read More

Biogen Selling Amevive Rights To Astellas For $60M, Royalties

Biogen Idec Inc. agreed to sell worldwide rights of its commercially disappointing psoriasis biologic, Amevive, to Astellas Pharma US Inc. in exchange for $60 million plus royalties. (BioWorld Today) Read More

The Medicines Co. Begins Phase III For Anticoagulant

Read More